Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$78.6M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$57.7M |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$22.5M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
+$15.4M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPHM
VIROPHARMA INC
VPHM
|
+$220M |
| 2 |
Gilead Sciences
GILD
|
+$48M |
| 3 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$35.3M |
| 4 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$24.5M |
| 5 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$24.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSRO
76
DELISTED
TESARO, Inc.
TSRO
| $882K | 0.01% |
31,218
| – | – |
|
77
Galectin Therapeutics
GALT
$371M
| $813K | 0.01% |
+100,600
| New | +$929K |
|
|
FMI
78
DELISTED
Foundation Medicine, Inc.
FMI
| $476K | 0.01% |
+20,000
| New | +$559K |
|
|
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $333K | ﹤0.01% |
+19,823
| New | +$246K |
|
|
SLXP
80
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $326K | ﹤0.01% |
3,621
| – | – |
|
|
CCXI
81
DELISTED
ChemoCentryx, Inc.
CCXI
| $290K | ﹤0.01% |
50,000
-150,000
| -75% | -$773K |
|
82
Gyre Therapeutics
GYRE
$733M
| – | – |
-2,626
| Closed | -$11M |
|
|
LITS
83
Lite Strategy Inc
LITS
$33.7M
| – | – |
-17,266
| Closed | -$3.88M |
|
|
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-586,936
| Closed | -$10.2M |
|
|
ARIA
85
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-1,333,703
| Closed | -$24.5M |
|
|
CBST
86
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-5,000
| Closed | -$318K |
|
|
VPHM
87
DELISTED
VIROPHARMA INC
VPHM
| – | – |
-5,592,239
| Closed | -$220M |
|
Similar funds
Julian Baker's Q4 2013 Portfolio in Review
As of Q4 2013, Julian Baker held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Julian Baker withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier.
Against the trend, Julian Baker opened a new position in DYAX CORPORATION worth $15.3M.
- Julian Baker's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
- Julian Baker added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
- Julian Baker's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
- Julian Baker fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
- Julian Baker's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
- Julian Baker opened 15 new positions and closed 6 in Q4 2013.
- Julian Baker's portfolio value rose 0.85% quarter-over-quarter to $7.1B.
Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.